^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AU-101

    i
    Other names: AU-101, AU101, AU 101, Autologous HER2-specific T cells, HER2-specific T cells, HER2 chimeric antigen receptor expressing T cell therapy, HER2-CART
    Associations

    News

    Trials
    Company:
    Aurora Biopharma, Baylor College of Medicine
    Drug class:
    HER2-targeted CAR-T immunotherapy, CD28-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over1year
    iCAR: T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=28 --> 10 | Trial completion date: Jan 2036 --> Apr 2037
    Enrollment closed • Enrollment change • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    AU-101
    almost4years
    iCAR: T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (clinicaltrials.gov)
    P1, N=28, Recruiting, Baylor College of Medicine | Trial completion date: Jan 2031 --> Jan 2036 | Trial primary completion date: Feb 2021 --> Feb 2026
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    AU-101
    over4years
    Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Baylor College of Medicine | Trial primary completion date: Jul 2020 --> Dec 2019
    Clinical • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    fludarabine IV • AU-101 • cyclophosphamide intravenous
    almost5years
    iCAR: T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (clinicaltrials.gov)
    P1, N=28, Recruiting, Baylor College of Medicine | Trial primary completion date: Feb 2020 --> Feb 2021
    Clinical • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    AU-101
    almost5years
    Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    fludarabine IV • AU-101 • cyclophosphamide intravenous